Showing results (351-360 of 447) with videos related to

Sort By:
Pageof 45
Cell Reports|June 7, 2023
Precise microdissection of gastric mixed adeno-neuroendocrine carcinoma dissects its genomic landscape and evolutionary clonal originsMiao-Zhen Qiu, Qingjian Chen, Dan-Yang Zheng, et al.
Cancer Research|October 20, 2022
The Macrophage-Associated LncRNA MALR Facilitates ILF3 Liquid-Liquid Phase Separation to Promote HIF1α Signaling in Esophageal CancerJia Liu, Ze-Xian Liu, Jia-Jun Li, et al.
Journal of the National Cancer Institute|December 12, 2018
Modulation of Redox Homeostasis by Inhibition of MTHFD2 in Colorectal Cancer: Mechanisms and Therapeutic ImplicationsHuai-Qiang Ju, Yun-Xin Lu, Dong-Liang Chen, et al.
Cancer Cell|April 14, 2023
An immunogenic and oncogenic feature-based classification for chemotherapy plus PD-1 blockade in advanced esophageal squamous cell carcinomaYan-Xing Chen, Zi-Xian Wang, Ying Jin, et al.
Lancet (London, England)|April 17, 2023
Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trialKohei Shitara, Florian Lordick, Yung-Jue Bang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 29, 2014
Lapatinib plus paclitaxel versus paclitaxel alone in the second-line treatment of HER2-amplified advanced gastric cancer in Asian populations: TyTAN--a randomized, phase III studyTaroh Satoh, Rui-Hua Xu, Hyun Cheol Chung, et al.
Cancer Letters|January 7, 2020
Inhibition of fatty acid catabolism augments the efficacy of oxaliplatin-based chemotherapy in gastrointestinal cancersYun Wang, Jia-Huan Lu, Feng Wang, et al.
Oncotarget|October 7, 2015
S-1 plus cisplatin versus fluorouracil plus cisplatin in advanced gastric or gastro-esophageal junction adenocarcinoma patients: a pilot studyYu Hong Li, Miao Zhen Qiu, Jian Ming Xu, et al.
Cancer Research and Treatment|June 24, 2026
A Multinational, Retrospective, Real-World Study: Treatment Patterns in Patients With HER2-Positive Locally Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Beyond First-line in East Asia (HER2+ GASTA Study)Do-Youn Oh, Winnie Yeo, Jen-Shi Chen, et al.
Nature Communications|November 5, 2024
YTHDF2 upregulation and subcellular localization dictate CD8 T cell polyfunctionality in anti-tumor immunityHaiyan Zhang, Xiaojing Luo, Wei Yang, et al.
Pageof 45